A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer).
In view of the activity of Cisplatin in bladder cancer a multicentre study of its less toxic analogue Carboplatin was carried out in 48 patients with metastatic transitional cell carcinoma, of whom 30 had received no previous cytotoxic chemotherapy. No complete remissions and only 3 partial responses were observed, suggesting that Carboplatin has only minimal activity in this disease.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D016190:Carboplatin; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000556:secondary
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin